Ann: Board Changes, page-18

First 18 Last

Share
Profile

Follow
daicosisgod

12,478 Posts.

1319

20/11/17

09:38

Post #: 28939952
Share

Originally posted by longshot41 ↑

Zman, I agree Chris took the company from making losses on turnover of aroun d $5 mil to $60.6 mil and making an EBITDA of a very respectable 9.5 mil in 5 years. Add to that attracting CBA and many other top tier funds with a SP of 44c when they were ready to take on the world via DCB.

Overnight they got smashed due to 100% of their traffic being paralysed by their client which was beyond their control and unforeseen. The double click compliance thing was expected and only had a modest impact on earnings.

So I think it's grossly unfair to blame Chris entirely and he has certainly taken a hit to his cred and wallet by stepping down as CEO after a passionate and exhaustive 5 years of success.

I don't know why he's moving on but I wish him the very best with his company in very good hands with Neil, who like Thorpey has a shitload of skin in the game and every reason to succeed.

Lets give Neil the benefit of the doubt at the AGM to see whether he can turn the ship around based on a much more sustainable and credible marketing business model, which is why I invested in the first place.

I'm betting their very best days are ahead.

Expand

Hi Longshot.

Who was the client that paralysed 100% of the DCB traffic? Just curious as I along with others invested in MBE because of DCB, which vanished into thin air overnight.

MBE Price at posting: 5.3¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 12 more messages in this thread...

First 18 Last

Add IMS (ASX) to my watchlist

Ann: Board Changes, page-18

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News